.png)
The truth about generalized anxiety disorder
In our third episode of Big Health Talks, two clinical experts discuss the standard of care for anxiety — and how it can be improved.
Welcome to the third segment of Big Health Talks, where we speak with clinical experts and benefits leaders about trends, challenges, and solutions in mental health care and the field of digital therapeutics (DTx).
In this episode, Jenna Carl, PhD, Chief Medical Officer at Big Health, is joined by Anu Asaani, PhD, Assistant Professor of Clinical Psychology at the University of Utah. They discuss everything you need to know about generalized anxiety disorder (GAD): what it is, who it affects, standard care options, myths and misconceptions, and predictions for the evolution of DTx as an effective treatment in the coming years.
What is GAD, and who does it affect?
What are the common treatments for GAD?
It seems to be a common myth that patients want medication as a quick fix for GAD. What is your experience with this?
Watch and listen to the entire conversation between Dr. Carl and Dr. Asaani below to learn more about the benefits of utilizing digital therapeutics to treat GAD.
Dr. Asaani is a paid consultant for Big Health.
During the COVID-19 public health emergency, Daylight is being made available as a treatment for generalized anxiety disorder (GAD) without a prescription. Daylight has not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of GAD.
DOC-3060 Effective 08/2023
Subscribe to blog
Here’s our latest
.jpeg)
%202%20(1).png)
During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.
1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.
DOC-3046 Effective 11/2023